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Abstract
This review examines recent attempts to advance the under-
standing of the mechanism by which neurones die in prion
disease. Prion diseases or transmissible spongiform encep-
halopathies are characterized by the conversion of a normal
glycoprotein, the prion protein, to a protease-resistant form
that is suggested to be both the infectious agent and the
cause of the rapid neurodegeneration in the disease. Death of
the patient results from this widespread neuronal loss. Thus
understanding the mechanism by which the abnormal form of
the prion protein causes neuronal death might lead to treat-
ments that would prevent the life-threatening nature of these
diseases.
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In the 1990s reviews of research in the field of prion diseases
rarely discussed the mechanism of neurodegeneration (Prus-
iner and DeArmond 1994). At first this would appear strange
because the fundamental threat that prion diseases present is
that they are fatal neurodegenerative conditions. However,
the prion protein (PrPc) was not sequenced until 1985 (Oesch
et al. 1985; Basler et al. 1986). The main bone of contention
in the field for many years was the suggestion made by
Stanley Prusiner that the abnormal isoform of this protein
(PrPSc) which could be isolated from the brain of mice
infected with mouse passaged scrapie (Bolton et al. 1982),
was the sole agent of infection (Prusiner 1982). All prion
diseases, including Creutzfeldt–Jakob disease (CJD), bovine
spongiform encephalopathy (BSE), scrapie in sheep and
chronic wasting disease (CWD) in deer, can be transmitted
from individual to individual or even across species by
injecting a brain extract from an infected individual into the
brain of another. Prion diseases are not naturally spread this
way, and indeed the majority of prion diseases including CJD
and scrapie are sporadic occurring with no evidence of
transmission of any kind. Nevertheless, research on the
mechanism by which prion disease can be transmitted
experimentally has continued with many people still reject-
ing the prion hypothesis, despite Stanley Prusiner winning
the Nobel Prize for his attempts to prove this theory (Prusiner
1998). The most convincing evidence for the role of the prion
protein in prion disease transmission comes from work with
mice in which PrPc expression was ablated or knocked out
(Büeler et al. 1992). In the absence of PrPc expression mice
are completely resistant to scrapie infection (Büeler et al.
1993). The reason for this is that there is no PrPc to be
converted to PrPSc. Clearly, understanding the conversion of
PrPc to PrPSc, either by exogenous PrPSc or by some other
mechanism, is central to understanding these diseases.
Although exogenous PrPSc is an important consideration
for investigations of the conversion process, sporadic
diseases where there is no exogenous PrPSc introduced will
not be explained by this. The first study to advance an
alternative suggested that metal substitution or loss of
binding at the copper binding site of PrPc might be sufficient
to generate an abnormal form of PrPc (Brown et al. 2000;
Brown 2001a).
Studies of neurodegeneration in prion disease advanced
little during this time. The first studies of neuronal death used
cell culture models (Müller et al. 1993; Forloni et al. 1993).
This approach has remained the preferred model for the
majority of investigators. Unfortunately, there has been little
crossover of ideas from the cell culture models to work with
animals, or at least little has been verified in animal models to
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date. Müller et al. (1993) showed that PrPSc is toxic to
cultured cells. This study was also the first to suggest that the
mechanism of cell death involved calcium entry via NMDA
receptors. The difficulty in isolating PrPSc and the general
inability to prove that it is pure has lead investigators to use
synthetic peptides. Forloni et al. (1993) identified a 21 amino
acid peptide (PrP106–126) that appeared to represent the
neurotoxic core of the protein. Since then virtually every
group studying neuronal death in prion diseases has either
used this peptide or sequences equivalent to it. Thus apart
from one very poorly controlled study (Kunz et al. 1999; see
Brown 1999) the neurotoxicity of this peptide has been
heavily and thoroughly reproduced. Indeed, the main con-
cern that this peptide is not neurotoxic in vivo has also been
shown to be false following a study showing that the
PrP106–126 peptide is toxic to cells in the retina of rats
(Ettaiche et al. 2000). Additionally, the mini-prion a 106
amino residue PrP expressed in transgenic mice retains the
106–126 region of the protein (Supattapone et al. 1999).
This PrP fragment is sufficient to induce prion disease and
neuronal death in vivo. My own research of the PrP106–126
peptide has been quite extensive, and has been reviewed
recently a number of times (Brown 2001b,c).
In parallel with PrP106–126, other short peptides that were
based on the sequence of PrPSc have also been studied.
However, the toxicity of other peptides was either found to
be much less than with PrP106–126 (Brown 2000a) or
dependent on mutations involved in inherited prion disease
(Forloni et al. 1999). In some cases different groups have
reported these peptides to be non-toxic (Forloni et al. 1993),
and others have reported that they are toxic (Pillot et al.
2000; Rymer and Good 2000). In absence of consistent
findings most interest has remained with PrP106–126.
PrP106–126 has many physiochemical qualities similar
to those of PrPSc. These include protease resistance, high
b-sheet content and the propensity to aggregate into fibrils
(Forloni et al. 1993; Tagliavini et al. 1993; De Gioia et al.
1994; Salmona et al. 1999). These findings show that in many
ways PrP106–126 is a good mimic of PrPSc. Such qualities
are clearly important considerations when considering the
neurotoxic nature of either PrPSc or PrP106–126. Aggregation
has been suggested to be important to the toxicity of PrP106–
126. However, it has also been shown that soluble non-
aggregated peptide is also important to toxicity (Brown et al.
1998a). However, others have argued that fabrillogenesis is
totally unnecessary for toxicity (Salmona et al. 1999). Thus,
although the physical state of PrP106–126 can mimic PrPSc it
is not clear whether this has relevance to neurotoxicity.
Research using PrP106–126 continues to be an expanding
field with many new groups proposing new insights or new
mechanisms for the action of this peptide. In the last year
alone there have been more than 25 publications on the
action of PrP106–126 (e.g. Haı̈k et al. 2000; Rymer and Good
2000; Bate et al. 2001; Brown 2001b,c; Deli et al. 2001;
Della-Bianca et al. 2001; Fabrizi et al. 2001; Gu et al. 2001;
Kourie et al. 2001; Le et al. 2001; O’Donovan et al. 2001;
Stewart et al. 2001; White et al. 2001). These different
mechanisms suggest a variety of factors that might be
involved. They range from interactions between PrP106–126
at the membrane, with proteins such as the p75 NGF receptor
(Della-Bianca et al. 2001), formyl peptide receptor-like 1
(Le et al. 2001), L-type calcium channels (Florio et al.
1996), extendin (Martins et al. 1997; Lopes et al. 2001),
laminin (Graner et al. 2000), vitronectin (Hajj et al. 2001),
PrP itself (Brown 2000b), or other proteins such as DNA
(Nandi 1997), tubulin (Brown et al. 1998b) and Bcl-2
(Kurschner and Morgan 1995). Additionally, it has been
suggested that the peptide binds to copper (Jobling et al.
2001; Brown 2000a) as has the whole protein (reviewed in
Brown 2001a). Indeed the list of proposed binding partners
for PrP (not just the peptide) has been growing and includes
dystrophin (Keshet et al. 2000), the laminin-receptor (Rieger
et al. 1997) and others (Yehiely et al. 1997). Clearly, this
expanding list requires rationalization. It is likely that many
of these interactions will prove to be artefacts that occur in
the test tube but have no physiological relevance. In
particular, the suggested interaction between Bcl-2 family
members and PrP is likely to be a pure artefact. Many
proteins bind to Bcl-2 family members simply as a result of
particular detergent conditions used during the isolation of
protein extracts (Hsu and Youle 1997). Unfortunately, the
more binding partners that are suggested for the protein or
the peptide, the less credibility any such proposed partner has
either in terms of the function of the protein or in terms of
activation of cell death pathways.
Other proposed mechanisms suggest that PrP106–126 can
either interact directly with the membrane (Rymer and Good
2000) and generate a transmembrane channel (Kourie and
Culverson 2000; Kourie et al. 2001) or can alter membrane
fluidity (Salmona et al. 1997). These effects are not irrecon-
cilable with other effects of the peptide. Indeed, given that
PrP106–126 is quite hydrophobic it is likely that the peptide
will readily enter the lipid bilayer. This hydophobicity might
explain why it readily binds to other proteins and explain the
multiple binding partners mentioned above. PrPc is normally
a glycosylphosphatidylinositol (GPI)-anchored protein teth-
ered to the cell surface without passing through it (Stahl
et al. 1990). Studies with full-length proteins have suggested
that under abnormal conditions PrP can also become
transferred into the membrane because of a potential stop
transfer element (STE). The domain which is then trans-
membrane is the same region that contains the PrP106–126
sequence (Hegde et al. 1998). Mutations in the prnp gene
have been shown to alter the proportion of PrP that can be
inserted in this transmembrane form. Unfortunately, the
relevance this has for disease remains disputed with reports
suggesting that at best only a few point mutations that are
linked to inherited forms of prion disease would lead to
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transmembrane PrP (Stewart and Harris 2000). Additional
claims that transmembrane PrP accounts for neurodegener-
ation in prion disease independent of association with
inherited mutations in the gene are still speculation (Hegde
et al. 1999). A recent paper has suggested that interaction
between PrP106–126 and PrPc expressed by neuronal-like
tumour cells over a period of four months (!) results in a form
of truncated PrP that could become transmembrane (Gu et al.
2001). However, a previous study (Brown 2000b) has shown
that such truncated PrP accumulates in aggregates of
PrP106–126 (after one day of exposure), which can be
readily separated from cells thus suggesting that this
truncated PrP is not a transmembrane form. Another report
shows that the same region of PrP proposed by Hegde et al.
(1999) to be transmembrane is neurotoxic (Haı̈k et al. 2000).
However, this peptide is virtually identical in sequence to
PrP106–126 and there is little to suggest that the majority of
peptide added by the authors to their cultures actually
becomes inserted in the membrane. Indeed these peptides
aggregate rapidly when added to a salt solution and float
around in clumps in the culture medium. Therefore neither of
these studies could be said to provide evidence that
transmembrane PrP is necessary for neurotoxicity.
Recently, some researchers have decided to investigate
further. Instead of just studying the direct effects of the
peptide on cells as if they were a mysterious black box, they
have chosen to look inside to see which effects might
actually proceed cell death. As has been mentioned already, a
number of studies have looked at calcium changes but there
seems to be some degree of lack of certainty: reports suggest
that calcium entry increases calcium release (Müller et al.
1993; Whatley et al. 1995) but others say that PrP106–126
reduces calcium release (Thellung et al. 2000). Although it
has been suggested that PrP can interact with Bax, another
study suggests that PrP106–126 causes mitochondrial depo-
larization (O’Donavan et al. 2001). Further downstream in
the cell-death pathway are the executors of cell suicide, the
caspases. There is now evidence that some of the caspases
become activated by PrP106–126 (White et al. 2001). This
finding is not unexpected as caspases are commonly involved
in cell death. Other findings from the same group suggest that
production of toxic arachidonic acid metabolic products
might be involved in cell death (Stewart et al. 2001).
Another more common theme is that of changes in
antioxidant proteins that would otherwise protect the neurone
from its oxidatively stressing environment (Brown et al.
1996; Perovic et al. 1997; Rizzardini et al. 1997).
How does one begin to distinguish the true mechanism of
neurodegeneration in prion disease from all of these possible
disparate observations? The first way is to identify those
changes that are reproducible between different research
groups and the second way is to show that the mechanism is
actually occurring in an animal with prion disease. At present
only a few such findings have been confirmed at either level.
PrP-knockout mice are resistant to prion infection (Büeler
et al. 1993). As these mice cannot generate PrPSc it is
difficult to determine whether PrPSc is toxic in the absence of
neuronal expression of PrPc in vivo. However, an ingenious
transplantation experiment showed that PrPc expression is
necessary for the toxicity of PrPSc (Brandner et al. 1996).
Transplantation of embryonic tissue from a mouse over-
expressing PrPc was made into a PrP-knockout mouse brain.
The transplanted tissue was then infected with mouse
scrapie. This transplanted tissue generated PrPSc and showed
signs of neurodegeneration and gliosis, whereas the PrP-
knockout brain surrounding it remained untouched by
neurodegeneration. PrPSc accumulated in the PrP-knockout
mice brains but this did not cause neurodegeneration. These
results show that neurones must express PrPc in order to be
killed by the agent of neurodegeneration in prion disease.
Assuming that this agent is solely PrPSc then PrPSc requires
neuronal expression of PrPc to be neurotoxic. PrP106–126
also requires neuronal expression of PrPc to be neurotoxic as
first shown in 1994 (Brown et al. 1994). This finding in
culture has also been shown for PrPSc itself (Giese et al.
1998) and has been verified by other groups (Jobling et al.
1999). As this finding has been confirmed in vivo, in vitro
and by a number of groups it can therefore be assumed that
neuronal PrPc expression is the first essential component of
the neurotoxic mechanism of PrP106–126. Thus any group
suggesting that they have found the mechanism of action of
PrP106–126 or PrPSc should confirm that their mechanism
does not occur in PrP-knockout neurones or in the absence
of PrPc expression.
Oxidative stress has been shown to be a hallmark of prion
diseases (Guentchev et al. 2000; Wong et al. 2001) as with
many neurodegenerative diseases. Numerous groups have
shown that PrP106–126 causes oxidative stress, disturbs the
expression of antioxidant proteins or that the toxicity of
PrP106–126 can be inhibited by antioxidants (Brown et al.
1996; Perovic et al. 1997). Cultures infected with PrPSc are
more susceptible to the toxicity of reactive oxygen species
(Milhavet et al. 2000). There is currently no evidence that
antioxidants can inhibit neuronal death in vivo. However, it
is clear that oxidative damage is involved in the mechanism
of PrP106–126 in the culture system. Therefore this is a
logical next component of the mechanism of action of the
peptide. There is little doubt that PrP106–126 causes cell
death via an apoptotic mechanism, and as the apoptosis of
neurones involves such changes as caspase activation (White
et al. 2001), mitochondrial depolarization (O’Donavan et al.
2001) and enhanced calcium entry through either NMDA
receptors (Müller et al. 1993) or L-type voltage gated
calcium channels (Brown et al. 1997) then it is logical to
assume that any or all of these changes might be induced by
the peptide or PrPSc. However, none of these changes are
specific and so can be safely termed as downstream events
that occur as a result of the triggering of apoptosis. Therefore
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although they are likely to be parts of the mechanism they are
not specific to prion disease.
As has been stated above, PrPSc-infected cells are more
sensitive to oxidative stress applied to the culture. This
suggests an indirect effect. Other studies have shown that
PrP106–126 reduces neuronal resistance to oxidative stress
(Brown et al. 1996). Thus the implication is that the toxic
effect is indirect as it requires oxidative stress to come from
outside the cell in order to initiate apoptosis. A number of
authors have stated that the peptide has a direct effect and
does not require these indirect stresses. However, such
statements are rather ignorant as a compromised antioxidant
defence on its own will not kill a cell, and many culture
systems might provide sufficient oxidative stress without
oxidative substances being added to the culture. Glutamine, a
common additive to culture medium, is rapidly converted to
glutamate. The levels of glutamate in most culture systems
are sufficient to activate a certain level of spontaneous
apoptosis (mediated by intracellular superoxide production)
in cells expressing NMDA receptors. Thus those researchers
who claim a direct effect that is independent of oxidative
damage must show that their mechanism cannot be inhibited
by antioxidants applied to their cultures. If antioxidants are
effective then it is clear that an indirect component is
involved.
Nevertheless, a direct component is necessary for the
toxicity of PrP106–126 as PrPc expression by neurones is
necessary for the toxicity to those neurones (Brown et al.
1994). It is this complexity that often frustrates those trying
to understand the mechanism of PrP106–126. Many assume
that a toxic mechanism must be X and does Y. However, it
appears that in prion disease it is more accurate to describe
the process as X does Y when Z has occurred. In this case X
is the increased production of an oxidative substance caused
by PrP106–126, Y is neuronal death and Z represents
reduced neuronal resistance to oxidative stress caused by
PrP106–126. Therefore those considering the neurotoxic
mechanism of this peptide must consider both a direct and an
indirect component to the mechanism. It is not sufficient to
simply assume that because one adds a peptide to an
apparently homogeneous population of cells and the cells die
that this is caused by a direct effect alone.
Microglial cells are activated by either PrP106–126 or
PrPSc. This finding has now also been repeated by a number
of groups (Brown et al. 1996; Giese et al. 1998; Combs
et al. 1999; Fabrizi et al. 2001). Activated microglia release
toxic substances such as superoxide or tumour necrosis factor
(TNF)-a, which might contribute to indirect toxic effects. In
particular microglia were suggested to be a component of the
first mechanism for PrP106–126 toxicity proposed (Brown
et al. 1996). It should be noted that when this model was first
proposed it was shown that microglia per se are NOT
essential, but that a source of oxidative stress (such as that
produced by microglia) was. Microglia also enhance the
toxicity of PrPSc (Giese et al. 1998) and microglia are
activated before the onset of neurodegeneration in mouse
scrapie (Williams et al. 1994; Giese et al. 1998). Since these
first reports, the finding that microglia can enhance the
toxicity of both PrPSc and PrP106–126 has been independ-
ently confirmed (Bate et al. 2001). This implies that this is a
reproducible effect confirming that an indirect effect of
substances released by microglia can contribute to the
neurotoxic mechanism of prion disease.
Thus, in summary, those components of the neurotoxic
mechanism of PrP106–126 or PrPSc that have been confirmed
and reproduced and which should be considered by anyone
investigating this topic are: (i) the peptide or PrPSc is not toxic
in the absence of PrPc expression; (ii) the mechanism involves
both direct and indirect effects; (iii) the indirect effects
include the generation of oxidative stess; (iv) the direct effects
result in reduced resistance to oxidative stress (see Fig. 1). In
the context of these confirmed findings the plethora of new
ideas about the mechanism need to be carefully assessed and
equated with this stand-point. It is to some degree absurd for
researchers to ignore the literature and to suggest that no
model of the mechanism currently exists. Thus, the onus is on
the proposers of these new models to disprove this model first.
However, clearly there are assumptions made in this model
that might be inadequate to describe the mechanism of
neurodegeneration in prion disease.
One of the big assumptions in all of the foregoing
discussion is that the toxicity of PrP106–126 is all that there
is to the toxicity of the prion protein. An important study
based on an animal model definitely shows that this is not the
case. Mice expressing a truncated form of PrP starting at
either amino-residue 121 or 136 in the mouse sequence on a
PrP-knockout background (i.e. no wild-type PrP is expressed
in these mice) show rapid neurodegeneration soon after birth
(Shmerling et al. 1998). The PrP expressed by these mice
lacks the PrP106–126 region but there is nevertheless clear
evidence that the C-terminal portion of PrP is neurotoxic. My
group has recently shown that the prion protein contains a
second toxic domain. This domain stretching around amino
residue 147–220 appears to be more toxic to neurones than
PrP106–126 (Daniels et al. 2001). This C-terminal fragment
is more toxic to neurones lacking expression of PrPc. This fits
with the observations of Shmerling et al. (1998) who
suggested that full-length PrPc inhibited the toxicity of
PrP121–231. Experiments with full-length recombinant PrPc
in culture also confirm this to be the case (Daniels et al.
2001). A more surprising finding, however, is that the
neurotoxic peptide PrP106–126 also inhibits the toxicity of
PrP121–231 (Daniels et al. 2001). Thus PrP not only has two
potentially neurotoxic domains but it is highly likely that in an
intact molecule these two domains neutralize each other in
terms of this potential neurotoxicity. Current studies of
neurodegeneration in prion disease do not take these obser-
vations into account. The toxicity of PrP121–231 is not
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sufficient or adequate to explain the toxicity of PrPSc. As
pointed out earlier PrPSc is not toxic to PrP-knockout
neurones. Nevertheless, the cell death that occurs in prion
diseases in vivo might not be explained by results from
in vitro studies of PrP106–126 or PrPSc alone. These recent
studies may change the focus of research away from
PrP106–126. What is yet to be determined is the extent of
which the new toxic domain contributes to neurodegener-
ation in vivo. It is quite possible that changes in the
secondary structure of PrPc when converted to PrPSc cause
the two toxic domains to be unmasked. It is quite possible
that in the presence of functional PrPc the more C-terminal
toxic domain is not involved in mediating cell death. Much
further research is needed to unravel the importance of these
new observations.
These discussions suggest that although many new
findings have emerged about the nature of neurodegeneration
in prion disease they have posed more questions than they
have provided answers. However, the myriad of new ideas
and new proposed mechanisms have thrown the field into a
perhaps cathartically necessary mayhem. However, from
among these many investigations certain clear paths to the
truth stand out. If researchers focus on these clear paths then
it is likely that important advances will be made. However, it
is possibly necessary that those research groups dedicated to
reaching these advances communicate and interact more. If
more groups continue to show for the first another possible
mechanism that they propose to be the answer then we are
likely to lose sight of the important question that remains to
be answered: How can neurodegeneration in prion disease
be prevented? The future of research into the field of prion
diseases has several clear targets. Meeting these are import-
ant for dealing with the threat of variant Creutzfeldt–Jakob
disease. These targets include: (i) diagnosing prion diseases
before clinical signs resulting from neuronal loss occur;
(ii) inhibiting neuronal loss in prion disease; (iii) reversing
clinical signs in prion disease. Clearly, these targets are all
dependent on a better understanding of changes in neurones
caused by abnormal forms of PrP. The in vitro models that
have been used for some years to study pathogenesis of prion
disease have now been shown to be relevant in vivo at a basic
level. It is now time to reassess what has been learned in vitro
and try to see if this information will bring us closer to
dealing with the targets indicated here.
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Pillot T., Drouet B., Pinçon-Raymond M., Vanderkerckhove J.,
Rosseneu M. and Chambaz J. (2000) A nonfibrillar form of the
fusogenic prion protein fragment [118–135] induces apoptotic cell
death in rat cortical neurons. J. Neurochem. 75, 2298–2308.
Prusiner S. B. (1982) Novel proteinaceous infectious particles cause
scrapie. Science 216, 136–144.
Prusiner S. B. (1998) Prions. Proc. Natl Acad. Sci. USA 95, 13363–
13383.
Prusiner S. B. and DeArmond S. J. (1994) Prion diseases and neuro-
degeneration. Ann. Rev. Neurosci. 17, 311–339.
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